Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today marks the end of Bleeding Disorders Awareness Month1. Recognised every March, this month aims to help raise awareness of inheritable blood and bleeding disorders and the 300 million people affected by them worldwide.
BPL granted a new patent in the US
30 March 2022
The United States Patent and Trademark Office granted a new patent (US Patent number: 11,149,079) to BPL for its ‘E+I’ process, granted in the US.
BPL Supports Rare Disease Day 2022
28 February 2022
Bio Products Laboratory (“BPL”), a leading manufacturer of plasma-derived protein therapies, celebrates Rare Disease Day in recognition of the critical role it plays in raising awareness for the 300 million people worldwide living with a rare disease, their families and their carers.
BPL Full Year 2021 Results: BPL delivers another strong performance
07 February 2022
Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the 12 months ended 31 December 2021, including the more recent developments since first half trading update issued in July.
BPL affiliate makes first ever sale to Mexico
04 February 2022
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced its first ever direct sale in Mexico as part of an important supply award of Zenalb® 20%.
BPL granted licence from the National Medical Products Administration (NMPA) to market ALBUMINEX® 25% product to China
24 January 2022
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX® 25% product to China.
PERMIRA FUNDS TO PARTNER WITH MARCUCCI FAMILY TO INVEST IN KEDRION BIOPHARMA AND BIO PRODUCTS LABORATORY
20 January 2022
20 January 2022 – Permira, the global private equity firm, today announces that funds advised by Permira, supported by their co-investor, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), have entered into a partnership with Kedrion’s existing shareholders (the Marcucci family and FSI) to jointly acquire and combine Kedrion and BPL. The combination will create a global player for medicines derived from human blood plasma, which treat patients with rare and life threatening conditions.
BPL to support the Immune Deficiency Foundation Research Grant Program
22 October 2021
The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (P.I.), including well-defined research projects with a specified benefit for improving the treatment, health, disease management, or diagnosis of people with P.I. management or diagnosis of people with primary immunodeficiency diseases.
Second Annual Hereditary Factor 10 Deficiency Awareness Day Kicks Off October 10
08 October 2021
Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, is proud to partner with the National Hemophilia Foundation in recognizing the second Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2021.